ArticleNucleic acids research2022
PharmacoDB 2.0: improving scalability and transparency of in vitro pharmacogenomics analysis.
Article in Nucleic acids research, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
19 citing papers in PubMed.
- CASER: A semi-supervised model with multi-omics data integration prioritizes cancer-associated epigenetic regulator genes.PLoS computational biology · 2026Article
- Multiomics Profiling of T-cell Leukemia and Lymphoma Enables Targeted Therapeutic Discovery.Cancer research · 2026Article
- DrugSurvPlot: A Novel Web-Based Platform Harnessing Drug Sensitivity Scores as Molecular Biomarkers for Pan-Cancer Survival Prognosis.Current gene therapy · 2026Article
- BiDRA: Bayesian inference as a robust alternative to non-linear regression for dose-response efficiency metrics assessment.Bioinformatics advances · 2026Article
- Pan-cancer analysis reveals netrin-1 receptors as potential tumor biomarkers and immune-related therapeutic targets.Scientific reports · 2025Article
- Current Bioinformatics Tools in Precision Oncology.MedComm · 2025Review
- Article
- BioBricks.ai: a versioned data registry for life sciences data assets.Frontiers in artificial intelligence · 2025Article
- Pharmacogenomics Tools for Precision Public Health and Lessons for Low- and Middle-Income Countries: A Scoping Review.Pharmacogenomics and personalized medicine · 2025Review
- Pan-Cancer Drug Sensitivity Prediction from Gene Expression using Deep Learning.bioRxiv : the preprint server for biology · 2024Article
- Facilitating integrative and personalized oncology omics analysis with UCSCXenaShiny.Communications biology · 2024Article
- Proteomic analysis of the urothelial cancer landscape.Nature communications · 2024Article
- CPADS: a web tool for comprehensive pancancer analysis of drug sensitivity.Briefings in bioinformatics · 2024Article
- Homologous Recombination Deficiency Unrelated to Platinum and PARP Inhibitor Response in Cell Line Libraries.Scientific data · 2024Article
- Spatial transcriptomics reveals distinct and conserved tumor core and edge architectures that predict survival and targeted therapy response.Nature communications · 2023Article
- CREAMMIST: an integrative probabilistic database for cancer drug response prediction.Nucleic acids research · 2023Article
- A glycosylation-related gene signature predicts prognosis, immune microenvironment infiltration, and drug sensitivity in glioma.Frontiers in pharmacology · 2023Article
- IMOPAC: A web server for interactive multiomics and pharmacological analyses of patient-derived cancer cell lines.Computational and structural biotechnology journal · 2023Article
- A deep tabular data learning model predicting cisplatin sensitivity identifies BCL2L1 dependency in cancer.Computational and structural biotechnology journal · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
16 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Cancer pharmacogenomics studies provide valuable insights into disease progression and associations between genomic features and drug response. PharmacoDB integrates multiple cancer pharmacogenomics datasets profiling approved and investigational drugs across cell lines from diverse tissue types. The web-application enables users to efficiently navigate across datasets, view and compare drug dose-response data for a specific drug-cell line pair. In the new version of PharmacoDB (version 2.0, https://pharmacodb.ca/), we present (i) new datasets such as NCI-60, the Profiling Relative Inhibition Simultaneously in Mixtures (PRISM) dataset, as well as updated data from the Genomics of Drug Sensitivity in Cancer (GDSC) and the Genentech Cell Line Screening Initiative (gCSI); (ii) implementation of FAIR data pipelines using ORCESTRA and PharmacoDI; (iii) enhancements to drug-response analysis such as tissue distribution of dose-response metrics and biomarker analysis; and (iv) improved connectivity to drug and cell line databases in the community. The web interface has been rewritten using a modern technology stack to ensure scalability and standardization to accommodate growing pharmacogenomics datasets. PharmacoDB 2.0 is a valuable tool for mining pharmacogenomics datasets, comparing and assessing drug-response phenotypes of cancer models.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.